Glyphic Biotechnologies Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
Series A
- Investors
-
36
Glyphic Biotechnologies General Information
Description
Operator of a biotechnology platform intended to increase binding affinity and improve consistency to help create personalized, precision cancer vaccines for patients of all backgrounds. The company's platform focuses on developing a single-molecule, massively parallel, de novo next-generation protein sequencing platform, enabling scientists and researchers to develop novel therapeutics and diagnostics and ultimately understand human biology and disease.
Contact Information
Website
www.glyphic.bioCorporate Office
- 3100 San Pablo Avenue
- Suite 201
- Berkeley, CA 94702
- United States
Corporate Office
- 3100 San Pablo Avenue
- Suite 201
- Berkeley, CA 94702
- United States
Glyphic Biotechnologies Timeline
Glyphic Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Early Stage VC (Series A) | 30-Sep-2025 | Completed | Generating Revenue | |||
| 11. Early Stage VC (Series A) | 23-Feb-2024 | Completed | Generating Revenue | |||
| 10. Grant | 15-Sep-2023 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | 22-Mar-2023 | Completed | Generating Revenue | |||
| 8. Grant | 02-Sep-2022 | Completed | Generating Revenue | |||
| 7. Grant | 11-Apr-2022 | Completed | Generating Revenue | |||
| 6. Grant | 19-Jan-2022 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 06-Dec-2021 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Nov-2021 | $6.03M | Completed | Generating Revenue | ||
| 3. Grant | 10-Nov-2021 | $50K | $6.03M | Completed | Generating Revenue |
Glyphic Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-1 | ||||||||
| Series A-2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Glyphic Biotechnologies Comparisons
Industry
Financing
Details
Glyphic Biotechnologies Competitors (6)
One of Glyphic Biotechnologies’s 6 competitors is Genopore, a Venture Capital-Backed company based in Yavne, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genopore | Venture Capital-Backed | Yavne, Israel | ||||
| Prisma (Biotechnology) | Venture Capital-Backed | Somerville, MA | ||||
| Portal Biotech | Venture Capital-Backed | London, United Kingdom | ||||
| Erisyon | Venture Capital-Backed | Austin, TX | ||||
| Encodia | Venture Capital-Backed | San Diego, CA |
Glyphic Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Glyphic Biotechnologies Patents
Glyphic Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026165279-A1 | Sequencing reagents and methods of use thereof | Pending | 30-Jan-2025 | ||
| WO-2026142980-A1 | Sequencing reagent conjugates and uses thereof | Pending | 23-Dec-2024 | ||
| WO-2026030423-A1 | Sequencing reagents using guanidinylating agents | Pending | 31-Jul-2024 | ||
| US-20260259218-A1 | Methods and systems for nanopore sequencing of modified amino acids | Pending | 31-Jan-2024 | ||
| AU-2025215927-A1 | Nanopore-based sequencing of peptides | Pending | 31-Jan-2024 | G01N33/6818 |
Glyphic Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Glyphic Biotechnologies Investors (36)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| In-Q-Tel | Not-For-Profit Venture Capital | Minority | ||
| Saraswati Ventures | Venture Capital | Minority | ||
| A-Level Capital | Venture Capital | Minority | ||
| Arben Ventures | Venture Capital | Minority | ||
| Bluebirds Capital | Venture Capital | Minority |
Glyphic Biotechnologies FAQs
-
When was Glyphic Biotechnologies founded?
Glyphic Biotechnologies was founded in 2021.
-
Where is Glyphic Biotechnologies headquartered?
Glyphic Biotechnologies is headquartered in Berkeley, CA.
-
What is the size of Glyphic Biotechnologies?
Glyphic Biotechnologies has 30 total employees.
-
What industry is Glyphic Biotechnologies in?
Glyphic Biotechnologies’s primary industry is Biotechnology.
-
Is Glyphic Biotechnologies a private or public company?
Glyphic Biotechnologies is a Private company.
-
What is the current valuation of Glyphic Biotechnologies?
The current valuation of Glyphic Biotechnologies is .
-
What is Glyphic Biotechnologies’s current revenue?
The current revenue for Glyphic Biotechnologies is .
-
How much funding has Glyphic Biotechnologies raised over time?
Glyphic Biotechnologies has raised $43.8M.
-
Who are Glyphic Biotechnologies’s investors?
In-Q-Tel, Saraswati Ventures, A-Level Capital, Arben Ventures, and Bluebirds Capital are 5 of 36 investors who have invested in Glyphic Biotechnologies.
-
Who are Glyphic Biotechnologies’s competitors?
Genopore, Prisma (Biotechnology), Portal Biotech, Erisyon, and Encodia are some of the 6 competitors of Glyphic Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
